MINDACT, validating a new prognostic tool

The trial enrolled 6,693 early-stage breast cancer patients

112 cancer centres and hospitals

9 countries

47 million € to fund the trial

46% of patients could be spared unnecessary chemotherapy

70-gene prognosis signature can help with decision-making about giving chemotherapy or not

Patient categories:

- Clinical & genomic tests indicate low risk of recurrence
- Clinical & genomic tests indicate high risk of recurrence
- Clinical & genomic tests are discordant

De-escalation of therapies
Pioneering precision medicine
Better and personalised treatment
Potential savings for society
Goldmine for future research

Highest scientific evidence level 1A